
Neurofibromatosis Type 1 - Pipeline Insight, 2024
Description
Neurofibromatosis Type 1 - Pipeline Insight, 2024
DelveInsight’s, “Neurofibromatosis Type 1 - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Neurofibromatosis Type 1 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Neurofibromatosis Type 1: Overview
Neurofibromatosis type 1 is a condition characterized by changes in skin coloring (pigmentation) and the growth of tumors along nerves in the skin, brain, and other parts of the body. The signs and symptoms of this condition vary widely among affected people. Beginning in early childhood, almost all people with neurofibromatosis type 1 have multiple café-au-lait spots, which are flat patches on the skin that are darker than the surrounding area. These spots increase in size and number as the individual grows older. Freckles in the underarms and groin typically develop later in childhood. Mutations in the NF1 gene cause neurofibromatosis type 1. The NF1 gene provides instructions for making a protein called neurofibromin. This protein is produced in many cells, including nerve cells and specialized cells surrounding nerves. Neurofibromatosis type 1 is considered to have an autosomal dominant pattern of inheritance. People with this condition are born with one mutated copy of the NF1 gene in each cell. In about half of cases, the altered gene is inherited from an affected parent. The remaining cases result from new mutations in the NF1 gene and occur in people with no history of the disorder in their family.
""Neurofibromatosis Type 1 - Pipeline Insight, 2021"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neurofibromatosis Type 1 pipeline landscape is provided which includes the disease overview and Neurofibromatosis Type 1 treatment guidelines. The assessment part of the report embraces, in depth Neurofibromatosis Type 1 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurofibromatosis Type 1 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Neurofibromatosis Type 1 R&D. The therapies under development are focused on novel approaches to treat/improve Neurofibromatosis Type 1.
This segment of the Neurofibromatosis Type 1 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Neurofibromatosis Type 1 Emerging Drugs
- Mirdametinib: SpringWorks Therapeutics
- NFX-179: NFlection Therapeutics
Further product details are provided in the report……..
Neurofibromatosis Type 1: Therapeutic Assessment
This segment of the report provides insights about the different Neurofibromatosis Type 1 drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Neurofibromatosis Type 1
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Neurofibromatosis Type 1: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neurofibromatosis Type 1 therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neurofibromatosis Type 1 drugs.
Neurofibromatosis Type 1 Report Insights
- Neurofibromatosis Type 1 Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Neurofibromatosis Type 1 drugs?
- How many Neurofibromatosis Type 1 drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neurofibromatosis Type 1?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neurofibromatosis Type 1 therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Neurofibromatosis Type 1 and their status?
- What are the key designations that have been granted to the emerging drugs?
- NFlection Therapeutics
- SpringWorks Therapeutics
- Shanghai Fosun Pharmaceutical Development Co, Ltd.
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Novartis
- Array BioPharma
- NFX 179
- Mirdametinib
- FCN-159
- AL2846
- Trametinib
- Binimetinib
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Neurofibromatosis Type 1: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Neurofibromatosis Type 1 – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Neurofibromatosis Type 1 companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Neurofibromatosis Type 1 Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- NPC-12: Nobelpharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Mirdametinib: SpringWorks Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Neurofibromatosis Type 1 Key Companies
- Neurofibromatosis Type 1 Key Products
- Neurofibromatosis Type 1- Unmet Needs
- Neurofibromatosis Type 1- Market Drivers and Barriers
- Neurofibromatosis Type 1- Future Perspectives and Conclusion
- Neurofibromatosis Type 1 Analyst Views
- Neurofibromatosis Type 1 Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.